Key result
ASE 2025 algorithm diagnoses HFpEF in ~36% of diabetic hypertensives, showing substantial agreement with EACVI.
Why the study?
Current HFpEF diagnostic algorithms differ substantially in assessing cardiovascular involvement, and the value of integrating speckle-tracking echocardiography parameters such as the Left Atrial Stiffness Index in patients with comorbid arterial hypertension and type 2 diabetes mellitus required evaluation.
Does the ASE 2025 diagnostic algorithm and additional assessment of the Left Atrial Stiffness Index (LASI) improve the diagnostic detection and agreement for HFpEF compared to the EACVI 2021 algorithm in patients with comorbid arterial hypertension and type 2 diabetes mellitus?
Observational (n=90)
Does the ASE 2025 diagnostic algorithm and additional assessment of the Left Atrial Stiffness Index (LASI) improve the diagnostic detection and agreement for HFpEF compared to the EACVI 2021 algorithm in patients with comorbid arterial hypertension and type 2 diabetes mellitus?
The EACVI 2021 and ASE 2025 algorithms show substantial agreement (kappa = 0.747) in diagnosing HFpEF among patients with hypertension and type 2 diabetes, and adding the Left Atrial Stiffness Index (LASI) may further optimize early detection of left atrial dysfunction.
Answers are grounded in this paper and cite their sources.
Algorithms show substantial agreement for HFpEF in hypertension with diabetes; leaves open whether LASI integration improves detection in prospective studies.
The prevalence of heart failure with preserved ejection fraction (HFpEF) is rapidly increasing and represents a major contemporary clinical challenge. Current diagnostic algorithms demonstrate substantial differences in their approaches to the comprehensive assessment of clinical and objective evidence of cardiovascular involvement. The integration of speckle-tracking echocardiography into diagnostic algorithms, through the assessment of left cardiac chamber function, particularly left atrial parameters, has become increasingly relevant. The aim of this study was to compare the prevalence of heart failure with preserved ejection fraction diagnosed using the algorithms of European Association of Cardiovascular Imaging (EACVI 2021) and the American Society of Echocardiography (ASE 2025), and to evaluate their agreement; to identify the diagnostic value of the additional assessment of the Left Atrial Stiffness Index (LASI); and to propose options for optimizing diagnostic strategies of heart failure with preserved ejection fraction in a cohort of patients with comorbid arterial hypertension (AH) and type 2 diabetes mellitus (T2DM). Materials and methods. The study included 90 patients (mean age 61.61 ± 7.94 years) presenting with symptoms and signs suggestive of heart failure in the setting of concomitant AH and T2DM. HFpEF was diagnosed using the EACVI 2021 and ASE 2025 diagnostic algorithms. In addition, the diagnostic value of a non-invasive marker of left atrial stiffness, LASI, was assessed. Results. The study demonstrated a high prevalence of HFpEF diagnosed according to both the EACVI 2021 (28.9 %) and ASE 2025 (35.5 %) algorithms in patients with AH and T2DM. A substantial agreement between the EACVI 2021 and ASE 2025 diagnostic algorithms was observed (Cohen’s kappa = 0.747). Early echocardiographic signs of left atrial dysfunction, reflected by an increased LASI, were identified. A potential approach for optimizing the existing diagnostic algorithms in this patient population was proposed. Conclusions. The EACVI 2021 and ASE 2025 algorithms demonstrated a substantial level of agreement in the diagnosis of HFpEF in a cohort of patients with concomitant AH and T2DM. The diagnostic value of additional assessment of LASI supports further investigation of this parameter as an adjunct marker for optimizing the diagnosis of HFpEF in this cohort.
No takes yet. Share an insight, caveat, or question.
Maistrovych et al. (2026) conducted an observational in Suspected heart failure with preserved ejection fraction (HFpEF) in comorbid arterial hypertension and type 2 diabetes mellitus (n=90). ASE 2025 diagnostic algorithm and Left Atrial Stiffness Index (LASI) assessment vs. EACVI 2021 diagnostic algorithm was evaluated on Prevalence of diagnosed HFpEF and diagnostic agreement between ASE 2025 and EACVI 2021 algorithms (Cohen's kappa = 0.747). The EACVI 2021 and ASE 2025 diagnostic algorithms identified HFpEF in 28.9% and 35.5% of hypertensive patients with type 2 diabetes, demonstrating substantial agreement.
Synapse has enriched 10 related papers. Consider them for comparative context: